$4.18
-0.03[-0.71%]
At close: Apr 25
$4.18
0[0.00%]
After Hours: 5:31PM EDT
BioCryst Pharma
(NASDAQ:BCRX)Latest News for BioCryst Pharma Stock (NASDAQ:BCRX)
BioCryst Pharma Stock (NASDAQ: BCRX)
Categories: All
Wednesday, April 10, 2024
Monday, February 26, 2024
- What's Going On With BioCryst Stock After Earnings?Erica Kollmann - Feb 26, 2024, 1:30PM
- 10 Health Care Stocks With Whale Alerts In Today's SessionBenzinga Insights - Feb 26, 2024, 12:35PM
- Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market SessionAvi Kapoor - Feb 26, 2024, 7:03AM
- BioCryst Forecasts Fiscal Year 2024 Orladeyo Net Revenue Of $380M-$400M, The Company Expects Operating Profit In 2024, Approaching Positive Eps And Positive Cash Flow In 2H 2025Benzinga Newsdesk - Feb 26, 2024, 7:02AM
- BioCryst Pharma Q4 Adjusted EPS $(0.28) Misses $(0.24) Estimate, Sales $93.40M Beat $90.01M EstimateBenzinga Newsdesk - Feb 26, 2024, 7:01AM
- Earnings Scheduled For February 26, 2024Benzinga Insights - Feb 26, 2024, 4:47AM
Friday, February 23, 2024
- A Preview Of BioCryst Pharma's EarningsBenzinga Insights - Feb 23, 2024, 2:01PM
- BioCryst Pharmaceuticals Says New Analyses Of Real-world Use Of Oral, Once-daily Orladeyo (Berotralstat) Showed Patients Who Initiated Orladeyo Experienced Rapid, Substantial And Sustained Reductions In Attack Rates Through 18 Months Of TreatmentBenzinga Newsdesk - Feb 23, 2024, 7:05AM
Tuesday, February 20, 2024
Monday, January 08, 2024
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Jan 8, 2024, 1:36PM
- BioCryst Pharmaceuticals shares are trading higher after the company issued preliminary Q4 revenue guidance above estimates. Also the company said it is approaching positive EPS and cash flow in 2H 2025.Benzinga Newsdesk - Jan 8, 2024, 11:55AM
- What's Going On With BioCryst Pharmaceuticals Stock?Erica Kollmann - Jan 8, 2024, 11:41AM
- Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price TargetBenzinga Newsdesk - Jan 8, 2024, 5:52AM
Friday, January 05, 2024
- BioCryst Pharmaceuticals Sees FY24 ORLADEYO Revenue $380M-$400M Vs $399.8M Est.Benzinga Newsdesk - Jan 5, 2024, 4:08PM
- Biocryst Pharmaceuticals Inc Does Not Intend To Draw Additional $150M Of Debt Available To It From Pharmakon; Company Expects Operating Profit In 2024, Approaching Positive EPS And Positive Cash Flow In 2H 2025Benzinga Newsdesk - Jan 5, 2024, 4:07PM
- BioCryst Announces Sees Prelim. Q4 ORLADEYO Revenue $89.9M Vs $89.33M Est.Benzinga Newsdesk - Jan 5, 2024, 4:03PM
- BioCryst Announces Sees Prelim. FY23 ORLADEYO Revenue $325M Vs $327.19M Est.Benzinga Newsdesk - Jan 5, 2024, 4:02PM
Wednesday, December 06, 2023
Thursday, November 30, 2023
- BioCryst Pharmaceuticals Says It Will Receive A 20% Royalty On Annual Japanese Sales Below A Prespecified Threshold And An 80% Royalty On Annual Japanese Sales Above Prespecified ThresholdBenzinga Newsdesk - Nov 30, 2023, 9:16AM
- CORRECTION: BioCryst Pharmaceuticals Ticker is "BCRXBenzinga Newsdesk - Nov 30, 2023, 9:13AM
- BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness ActivitiesBenzinga Newsdesk - Nov 30, 2023, 9:11AM
Wednesday, November 29, 2023
Monday, November 20, 2023
Monday, November 06, 2023
Friday, November 03, 2023
- BioCryst R&D Day Highlights New Diversified Pipeline Of First-In-Class/Best-In-Class Therapies With Five Programs Expected In Clinical Development In Next 24 MonthsBenzinga Newsdesk - Nov 3, 2023, 12:05PM
- BioCryst And Clearside Biomedical Enter Partnership To Develop Avoralstat For Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector; SCS Microinjector Is The First And Only FDA-Approved Approach To Access The Suprachoroidal SpaceBenzinga Newsdesk - Nov 3, 2023, 12:02PM
Thursday, November 02, 2023
- BioCryst Expects To Achieve No Less Than $320M In FY23 Orladeyo Revenue And $1 Billion In Peak Orladeyo RevenueBenzinga Newsdesk - Nov 2, 2023, 7:12AM
- BioCryst Pharma Q3 Adjusted EPS $(0.19) Beats $(0.23) Estimate, Sales $86.74M Beat $85.95M EstimateBenzinga Newsdesk - Nov 2, 2023, 7:11AM
- Earnings Scheduled For November 2, 2023Benzinga Insights - Nov 2, 2023, 4:56AM
Friday, October 27, 2023
Thursday, October 26, 2023
Tuesday, October 10, 2023
Thursday, October 05, 2023
Tuesday, October 03, 2023
Monday, September 25, 2023
Monday, September 18, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023Benzinga Insights - Sep 18, 2023, 11:00AM
- RBC Capital Upgrades BioCryst Pharma to Outperform, Raises Price Target to $10Benzinga Newsdesk - Sep 18, 2023, 7:16AM
- The Institut National D'excellence En Santé Et Services Sociaux Has Issued Positive Recommendation For Biocryst Pharmaceuticals' Orladeyo (Berotralstat) To Be Reimbursed For The Prevention Of Hereditary Angioedema Attacks In Adults And Pediatric PatientsBenzinga Newsdesk - Sep 18, 2023, 7:02AM
Tuesday, August 08, 2023
Friday, August 04, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2023Benzinga Insights - Aug 4, 2023, 11:01AM
- RBC Capital Maintains Sector Perform on BioCryst Pharma, Raises Price Target to $9Benzinga Newsdesk - Aug 4, 2023, 10:36AM
- Jefferies Upgrades BioCryst Pharma to Buy, Announces $11 Price TargetBenzinga Newsdesk - Aug 4, 2023, 8:41AM
- HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price TargetBenzinga Newsdesk - Aug 4, 2023, 6:14AM